Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 10000 anti-xa iu/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 7500 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 12500 anti-xa iu - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 15000 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 18000 anti-xa iu - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 2500 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - dalteparin sodium (unii: 12m44vtj7b) (dalteparin - unii:s79o08v79f) - dalteparin sodium 2500 [iu] in 0.2 ml - fragmin injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-q-wave myocardial infarction, when concurrently administered with aspirin therapy [see clinical studies (14.1)] . fragmin is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): fragmin is indicated for the extended treatment of symptomatic venous thromboembolism (vte) (proximal dvt and/or pe), to reduce the recurrence of vte in adult patients with cancer. in these patients, the fragmin therapy begins with the initial vte treatment and continues for six months [see clinical studies (14.5)] . fragmin is indicated for the treatment of symptomatic venous thromboembolism (vte) to reduce the recurrence of vte in pediatric patients 1 month of age and older. fragmin is not indicated for the acute treatment of vte. fragmin is contraindicated in: risk summary available data from published literature and postmarketing reports have not reported a clear association wit

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 5000 anti-xa iu - injection, solution - excipient ingredients: water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

United States - English - NLM (National Library of Medicine)

pfizer, inc. - dalteparin sodium (unii: 12m44vtj7b) (dalteparin - unii:s79o08v79f) - 2500 [iu] in 0.2 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - dalteparin sodium - solution for injection - 25000unit/1ml